Liminatus Pharma receives Nasdaq delinquency notice for late Q2 10-Q filing; has 60 days to submit compliance plan

Liminatus Pharma, Inc.

Nasdaq notified Liminatus on Aug 22, 2025 of non-compliance with Listing Rule 5250(c)(1) due to delayed Form 10-Q for period ended June 30, 2025.
Company has 60 days, until Oct 21, 2025, to submit a plan to regain compliance; Nasdaq may grant extension to Feb 16, 2026 if plan accepted.
Common stock (LIMN) continues to trade on Nasdaq; no immediate delisting effect.
Liminatus is a pre-clinical stage biopharma developing immune-modulating cancer therapies.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.